Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia

Chest

Volumn 112, Issue 2, 1997, Pages 406-415

  Van Den Brande, Paul ^a,b   Vondra, Vladimir ^c   Vogel, Friedrich ^d   Schlaeffer, Francisc ^e   Staley, Heather ^f   Holmes, Catherine ^f  

^a Pulmonary Division   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Medizinische Klinik III   (Germany)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antibiotic treatment; Cefuroxime; Cefuroxime axetil; Community acquired pneumonia; Sequential therapy

Indexed keywords

CEFUROXIME; CEFUROXIME AXETIL;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; EUROPE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; TREATMENT OUTCOME; VOMITING;

EID: 0030757813     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.2.406     Document Type: Article

References (39)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-24
2. Wilson DO. Issues in infections disease: community-acquired pneumonia. Fam Pract Recert 1993; 15:31-50
3. Vogel F, Reetz KP, Muller T. Oral follow-up therapy with cefuroxime axetil in the treatment of bacterial infections in the clinic. Infektions Klinik 1991; 4:3-14
4. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33:169-77
5. American Thoracic Societv. ATS guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Ann Rev Respir Dis 1993; 148:1418-26
6. Lew D. Opportunities for IV to oral switch in the management of infections: the role of quinolones. Int J Antimicrob Agents 1994; 4:S53-57
7. Conly JM, Low DE. Intravenous-to-oral antimicrobial stepdown therapy: improving the quality of care and reducing costs. Can J Infect Dis 1995; 6(suppl A):3-5
8. McCracken GH. New era for orally administered antibiotics: use of sequential parenteral-oral antibiotic therapy for serious infectious disease of infants and children. Paediatr Infect Dis J 1987; 6:951-53
9. Miller A, Hancock F. Sequential therapy for significant infection: a comparison of the efficacy, safety profile and cost of intravenous followed by oral cefuroxime versus cefoxtaxime [abstract 664]. Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 1995
10. Ehrenkranz NJ, Nerenberg DE, Shultz JM, et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992; 13:21-32
11. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22:219-23
12. Quintiliani R, Crowe HM, Nightingale C. Transitional antibiotic therapy. Can J Infect Dis 1995; 6(suppl A):6-10
13. Jewesson PJ. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995; 6(suppl A):11-16
14. Stein GE, Mantz SL. Antibiotic utilization and cost analysis in hospitalized patients with community acquired pneumonia. Hosp Pharmacy 1995; 30:132-34
15. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic stepdown therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29:561-65
16. Helio S, Jones RN, Washington JA, et al. In vitro activity of cefpodoxime compared with other cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis 1993; 17:143-50
17. Smith BR, Le Frock CL. Cefuroxime: antimicrobial activity, pharmacology and clinical efficacy. Ther Monitor 1983; 5:149-60
18. Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents 1994; 4:23-36
19. Stille W, Kranz-Jansen M, Maass A-B, et al. Sequential therapy of community-acquired pneumonia: intravenous cefuroxime versus intravenous cefuroxime followed by cefuroxime axetil: recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy, Stockholm, 1993; 43-44
20. Brambilla C, Kastanakis S, Knight S, et al. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992; 11:118-24
21. Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158;831-47
22. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96
23. O'Callaghan CH, Harding SM. The pharmacokinetics of cefuroxime in man in relation to its antibacterial activity. Proc R Soc Med 1977; 70(suppl 9):4-10
24. Harding SM, Harris AM, Hassani H. The bioavailability and pharmacokinetics of cefuroxime from RS3 tablets of cefuroxime axetil: a profile of cefuroxime axetil in general practice [poster]. Proc R Coll Phys Symp, 1988
25. Hajirousso V, Joshi RC, Bullas J, et al. Cefuroxime in the treatment of lower respiratory tract infections. In: Cefuroxime update: Royal Society of Medicine International Congress and Symposium Series (No. 38). London: Academic Press, 1981; 123-33
26. Walstad R, Thurmann-Nielsen E, Vilsvik J, et al. Pharmacokinetics of cefuroxime axetil in patients with LRTI. Proc R Coll Phys Symp, 1988; 65-67
27. Winter J, Dhillon P. Penetration of cefuroxime into bronchial mucosa following oral administration of cefuroxime axetil. J Antimicrob Chemother 1991; 27:556-58
28. Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Stat Med 1984; 3:199-214
29. Breslow NE, Day NE. Statistical methods in cancer research: the analysis of case-control studies (Vol 1). Lyon: International Agency for Research on Cancer, 1980
30. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48
31. Kohl KF, Kohler CO. A multicentre clinical trial to compare antibiotic regimens in patients with LRTIs: cefuroxime IV followed by cefuroxime axetil vs cefotiam IV [abstract 1821]. In: Programme and Abstracts of the 17th International Congress of Chemotherapy, Berlin, 1991
32. Clearhout P, Debaere P, Lemye R, et al. A prospective study of intramuscular cefuroxime followed by cefuroxime axetil per os in the treatment at home of lower respiratory tract infections. In: Programme of the Sixth European Congress of Clinical Microbiology and Infectious Diseases, Seville, 1994; 28-31
33. Ducroix JP, Martin F, Smail A, et al. Treatment of community acquired pneumonia with cefuroxime (i.m.) followed by cefuroxime axetil (p.o.) [abstract 1344]. In: Programme and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, 1990
34. Shalit I, Dagan R, Engelhard D, et al. Cefuroxime efficacy in pneumonia: sequential short-course IV/oral suspension therapy. Isr J Med Sci 1994; 30:684-89
35. Vogel F. Sequential therapy in the hospital management of lower respiratory tract infections. Am J Med 1995; 99(suppl B):14S-19S
36. Appelbaum PC. Antimicrobial resistance to Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15:77-83
37. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99(suppl B):35-75
38. O'Callaghan CH, Sykes RB, Ryan DM, et al. Cefuroxime - a new cephalosporin antibiotic. J Antibiot 1976; 29:29-37
39. Raz R, Atar S, Schaeffer S, et al. The economic impact of cefuroxime axetil following cefuroxime IV in the treatment of patients with respiratory tract infections [abstract 219]. In: Programme and Abstracts of the Eighth Mediterranean Congress of Chemotherapy, Barcelona, 1990